Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 Net Margin % is 31.36% as of Dec. 2025, which is 9% above its 10-year median of 28.66. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.11 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 960 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 95.52% on this metric.
The historical rank and industry rank for Consun Pharmaceutical Group's Net Margin % or its related term are showing as below:
CPHGF'
s Net Margin % Range Over the Past 10 Years
Min: 4.62 Med: 28.66 Max: 31.55
Current: 31.55
CPHGF's Net Margin % is ranked better than 95.52% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs CPHGF: 31.55
Consun Pharmaceutical Group (OTCPK:CPHGF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Consun Pharmaceutical Group Net Margin % Related Terms
Consun Pharmaceutical Group Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a Net Margin % of 31.36% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Consun Pharmaceutical Group and its competitors. This is near median its historical median of 28.66. Over the past decade, Consun Pharmaceutical Group's Net Margin % has ranged from 4.62 to 31.55. According to the industry distribution chart, Consun Pharmaceutical Group ranks #43 out of 960 companies in the Drug Manufacturers industry, placing it in the top 4.5%.
Is Consun Pharmaceutical Group's Net Margin % too high?
Consun Pharmaceutical Group's current Net Margin % of 31.36% is near median its 10-year median of 28.66. Over the past 10 years, this metric has ranged from a low of 4.62 to a high of 31.55. The Drug Manufacturers industry median Net Margin % is 5.64. Consun Pharmaceutical Group's value of 31.36% is 456.5% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #43 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #43 out of 960 companies for Net Margin %. This places Consun Pharmaceutical Group in the top 5% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.64. Consun Pharmaceutical Group's value of 31.36% is 456.5% above this benchmark. Historically, Consun Pharmaceutical Group's own Net Margin % has ranged from 4.62 to 31.55 over the past decade. While the company's 10-year median is 28.66 vs. the industry median of 5.64, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Net Margin % of 31.36% is 456.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Net Margin % is 31.36%, which is near median its own 10-year median of 28.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.11, compared to a current price of $1.80 — trading 62.2% above its estimated fair value. The current Net Margin % is 31.36%, which is near median its 10-year median of 28.66 and 456.5% above the Drug Manufacturers industry median of 5.64. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Net Margin % is 31.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 62.2% above its estimated GF Value™ of $1.11.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Net Margin %: 31.36% (near median its 10-year median of 28.66)
GF Value™: $1.11 vs. price of $1.80 (62.2% above fair value)
Industry Position: 456.5% above the Drug Manufacturers median (#43 of 960)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
